Novo Nordisk A/S (NYSE:NVO) is Wisconsin Capital Management LLC’s 7th Largest Position

Wisconsin Capital Management LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 0.3% during the third quarter, Holdings Channel.com reports. The fund owned 67,029 shares of the company’s stock after purchasing an additional 200 shares during the quarter. Novo Nordisk A/S accounts for approximately 4.2% of Wisconsin Capital Management LLC’s investment portfolio, making the stock its 7th largest position. Wisconsin Capital Management LLC’s holdings in Novo Nordisk A/S were worth $7,981,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NVO. Advisor OS LLC lifted its position in Novo Nordisk A/S by 0.6% during the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after acquiring an additional 82 shares during the period. Cascade Financial Partners LLC boosted its position in shares of Novo Nordisk A/S by 2.3% in the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after purchasing an additional 84 shares in the last quarter. Novare Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after buying an additional 85 shares during the last quarter. AA Financial Advisors LLC increased its position in Novo Nordisk A/S by 3.2% during the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock valued at $400,000 after buying an additional 86 shares in the last quarter. Finally, Steel Grove Capital Advisors LLC raised its stake in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after buying an additional 86 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, October 10th. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $110.15 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The stock’s 50-day simple moving average is $123.24 and its 200-day simple moving average is $130.76. The company has a market capitalization of $494.30 billion, a price-to-earnings ratio of 37.72, a PEG ratio of 1.46 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, analysts expect that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.